Drugs / XL309
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05932862 | Apr 2024 → Jan 2029 expected | neoplasm | Exelixis | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-03-25 | Exelixis | Results Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025 exelixis.com ↗
The findings demonstrate activity of XL309 alone or in combination with PARP or topoisomerase inhibitors. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-03-25 | Exelixis | Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025 exelixis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XL309 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05932862 ↗ |
| Route | Oral | “XL309 will be administered orally per assigned schedule.” NCT05932862 ↗ |